BIBW2992 inhibits ERBB2 and EGFR and targets at EGFR signaling pathway (Iorio et al., 2016) and has been widely investigated for cancers, like lung cancer and melanoma (Rinehart et al., 2004; Nehs et al., 2010; Varmeh et al., 2016). Here, EGFR is linked to lung carcinoma.